Accessibility Menu
Sanara MedTech logo

Sanara MedTech(NASDAQ) SMTI

Market Cap$313.96MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1992)-96%
5 Year+10%
1 Year+8%
1 Month+37%
$34.24
+0.20%
+0.07Today
Sanara MedTech last closing stock price
MetricPriceDate
Last closeUSD 34.172026-08-18
Sanara MedTech stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.61%USD 34.382026-08-11
1 month+36.68%USD 25.002026-07-17
3 month+48.57%USD 23.002026-05-20
Year to date+46.34%USD 23.352025-12-31
1 year+8.2%USD 31.582025-08-18
3 year-14.04%USD 39.752023-08-18
5 year+9.66%USD 31.162021-08-19
Since inception-96.37%USD 937.501992-05-01

Sanara MedTech Financials at a Glance

Market Cap

$313.96MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$109.81M

Net Income (TTM)

-$32.01M

EPS (TTM)

-$3.71

P/E Ratio

-9.21

Dividend

$0.00

Beta (Volatility)

1.15 (Average)

Price

$34.24

Volume

32,505.243

Open

$34.20

Previous Close

$34.17

Daily Range

$34.18 - $34.28

52-Week Range

$16.05 - $35.95

Estimated Earnings Date

Nov 11, 2026

SMTI News

Foolcom-Featured.png

Sanara MedTech Sales Jump 28 Percent

Motley Fool Markets TeamAug 13, 2025

SMTI: Motley Fool Moneyball Superscore

59

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Sanara MedTech

Sanara MedTech makes wound and skin care products for hospitals and clinics. Its products help doctors treat surgical wounds and chronic ulcers. These solutions aim to speed up healing and reduce complications for patients.

Wound Wonders: What Sanara Sells

  • Soft Tissue Repair (88.6% of revenue): Collagen powders, gels, and advanced dressings for surgical wounds and ulcers, used by hospitals and clinics.
  • Bone Fusion (11.4% of revenue): Bioactive bone grafts and matrices to support bone healing in surgeries, targeting orthopedic and spine specialists.
  • Antimicrobial Solutions: Cleansers and gels that help prevent infection in wounds, used in both acute and post-acute care settings.
  • Amniotic and Extracellular Matrix Products: Tissue-based sheets and flowable materials for complex wound repair, often used in advanced surgical cases.
  • Other Products: Additional wound care items with minimal revenue impact, serving niche clinical needs.

Growth Spurts and Strategic Moves

  • Acquired CarePICS in April 2025 to expand digital wound care capabilities.
  • Invested in Biomimetic Innovations Limited and ChemoMouthpiece, LLC for new product access in 2025.
  • Discontinued value-based wound care services (THP) in September 2025 after persistent losses.
  • Secured exclusive U.S. rights for OsStic BioAdhesive through partnership with Biomimetic Innovations Limited in 2025.
  • Filed 11 new provisional patent applications in 2024, converting them to non-provisional applications in 2025.

What Makes Sanara Stand Out

Sanara distributes its products to over 4,000 U.S. hospitals through a broad network. The company focuses on biologically active wound care and bone repair, supported by clinical studies. Its strategy centers on in-house research, exclusive licensing, and a single, focused business segment.

Five Things You Need to Know

  • Net revenue was $103.1 million in 2025, up 19% from 2024.
  • Soft tissue repair products made up 88.6% of 2025 revenue.
  • Gross margin reached 93% in 2025, up from 91% in 2024.
  • Adjusted EBITDA was $17.0 million in 2025, up 86% from 2024.

Bottom Line

Sanara has shifted to focus on surgical wound and bone care, exiting unprofitable segments. The company’s growth relies on innovation, clinical validation, and expanding its hospital network.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

108

CEO

Seth D. Yon

Website

www.sanaramedtech.com

Headquarters

Fort Worth, TX 76102, US

SMTI Financials

Key Financial Metrics (TTM)

Gross Margin

91.33%

Operating Margin

9.36%

Net Income Margin

-29.15%

Return on Equity

-473.55%

Return on Capital

16.90%

Return on Assets

-46.30%

Earnings Yield

-10.86%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$313.96MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

9.19M

Volume

32.51K

Avg. Volume

177.76K

Financials (TTM)

Gross Profit

$100.29M

Operating Income

$10.28M

EBITDA

$9.46M

Operating Cash Flow

$5.69M

Capital Expenditure

-$1.19M

Free Cash Flow

$4.50M

Cash & ST Invst.

$15.42M

Total Debt

$48.53M

Sanara MedTech Performance Analysis

Sanara MedTech annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 45,842,84589.9%
20232023-12-31USD 64,989,84241.8%
20242024-12-31USD 86,672,42533.4%
20252025-12-31USD 103,117,98219.0%
Sanara MedTech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-301.9%
Q42025-12-314.6%
Q12026-03-310.9%
Q22026-06-301.2%
Sanara MedTech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.00-7.0%
20232023-12-31USD -0.52-48.2%
20242024-12-31USD -1.14119.1%
20252025-12-31USD -4.36282.4%
Sanara MedTech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-1430.4%
Q42025-12-3194.3%
Q12026-03-31125.5%
Q22026-06-30-198.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$28.14M

+8.9%

Gross Profit

$26.16M

+9.5%

Gross Margin

92.96%

N/A

Market Cap

$313.96MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.91M

N/A

Employees

108

N/A

Net Income

-$452.86K

+77.5%

EBITDA

$2.02M

+127.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$15.42M

-9.1%

Total Debt

$48.53M

+6.8%

Accounts Receivable

$12.57M

+4.8%

Inventory

$3.46M

-1.5%

Long Term Debt

$48.15M

+6.4%

Short Term Debt

$383.15K

+109.4%

Return on Assets

-46.30%

N/A

Return on Invested Capital

18.15%

N/A

Free Cash Flow

$2.03M

+125.2%

Operating Cash Flow

$2.04M

-23.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TRDAEntrada Therapeutics, Inc.
$7.55+3.85%
VMDViemed Healthcare, Inc.
$9.06-0.71%
HITIHigh Tide Inc.
$2.43+1.04%
NEONeoGenomics, Inc.
$16.28+2.39%

Trending Stocks

Symbol / CompanyPricePrice Chg
MRNAModerna
$138.42+1.20%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$46.85+0.06%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$121.66-0.06%
KORUDirexion Shares ETF Trust - Direxion Daily Msci South Korea Bull 3x Shares
$19.25+0.08%

Questions About SMTI

What is the current price of Sanara MedTech?

Sanara MedTech is trading at $34.24 per share.

What is the 52-week range for Sanara MedTech?

Over the past 52 weeks, Sanara MedTech has traded between $16.05 and $35.95.

How much debt does Sanara MedTech have?

As of the most recent reporting period, Sanara MedTech reported total debt of $48.53M.

How much cash does Sanara MedTech have on hand?

Sanara MedTech reported $15.42M in cash and cash equivalents in its most recent financial results.

What is Sanara MedTech’s dividend yield?

Sanara MedTech does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services